Extended Data Fig. 3: Neonatal systemic administration of AAV-μUtro in mdx mice shows histopathological amelioration in limb and diaphragm muscle eight weeks post injection.
From: Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models
a, Double immunofluorescence staining against an epitope shared by native and recombinant utrophin (Utro_N) and an epitope unique to native utrophin (Utro_C) of the entire tibialis anterior muscle. Scale bar, 100 μm. b, Representative immunofluorescence staining of sectioned diaphragm35 at two distinct vector doses per mouse. Scale bar, 50 μm. All experiments were repeated independently at least two times with similar results.
